Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$78.97

0.435 (0.55%)

10:33
10/18/16
10/18
10:33
10/18/16
10:33

Eli Lilly announces $90M investment in Lilly Global Health Partnership

Eli Lilly announced a plan to increase access to quality health care and to improve long-term health for millions of people worldwide, with an aim to reach 30 million people in resource-limited settings annually by 2030. The cornerstone of this goal - known as "Lilly 30x30" - is a new five-year, $90M investment in the Lilly Global Health Partnership, which will improve access to treatment for diabetes, cancer and tuberculosis. One-half of the $90M commitment will come from the Eli Lilly and Company Foundation; the other half will come from company funds. The $90M investment will accelerate the company's and the Foundation's global health work with key international, national and local partners. The Lilly Global Health Partnership will expand current work in diabetes and TB and add cancer as a new therapeutic area of focus. To reach 30M people annually in communities with limited resources - a six-fold increase over the number reached today - Lilly will explore new approaches within different areas of its business, the company added.

  • 25

    Oct

  • 06

    Nov

LLY Eli Lilly
$78.97

0.435 (0.55%)

09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.

TODAY'S FREE FLY STORIES

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

, QCOM

Qualcomm

$68.25

2.87 (4.39%)

14:51
01/17/18
01/17
14:51
01/17/18
14:51
Periodicals
Broadcom tells Bloomberg FTC review 'immaterial to business' »

In an emailed statement…

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

QCOM

Qualcomm

$68.25

2.87 (4.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

PVG

Pretium Resources

$11.61

-0.04 (-0.34%)

14:45
01/17/18
01/17
14:45
01/17/18
14:45
Options
Pretium Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
01/17/18
01/17
14:45
01/17/18
14:45
General news
Breaking General news story  »

Chicago Federal Reserve…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

, GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

14:39
01/17/18
01/17
14:39
01/17/18
14:39
Hot Stocks
Google introduces Cloud AutoML to help businesses use machine learning »

In a blog post, Google…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

CBS

CBS

$59.44

0.01 (0.02%)

, VIAB

Viacom

$31.38

-2.38 (-7.05%)

14:37
01/17/18
01/17
14:37
01/17/18
14:37
Periodicals
Shari Redstone renews push to merge CBS, Viacom, WSJ reports »

Shari Redstone is…

CBS

CBS

$59.44

0.01 (0.02%)

VIAB

Viacom

$31.38

-2.38 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 15

    Feb

JBHT

J.B. Hunt

$120.64

-0.42 (-0.35%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Technical Analysis
Technical Earnings Preview: J.B. Hunt near life highs before earnings »

At time of writing and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$31.91

-0.44 (-1.36%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Hot Stocks
Deason reports 6% stake in Xerox, demands disclosure of JV pact with Fujifilm »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
01/17/18
01/17
14:35
01/17/18
14:35
General news
Treasury Action: yields held near highs »

Treasury Action: yields…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

, VNRX

VolitionRx

$2.95

0.0441 (1.52%)

14:31
01/17/18
01/17
14:31
01/17/18
14:31
Hot Stocks
Analysts stay bullish on Exact Sciences after ASCO abstract prompts pullback »

Shares of Exact Sciences…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

VNRX

VolitionRx

$2.95

0.0441 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

  • 29

    Mar

AG

First Majestic

$7.36

0.0106 (0.14%)

14:30
01/17/18
01/17
14:30
01/17/18
14:30
Options
Far upside call buyers in First Magestic as shares trade flat »

Far upside call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$71.16

-0.05 (-0.07%)

14:26
01/17/18
01/17
14:26
01/17/18
14:26
Hot Stocks
Vornado raises dividend to 63c per share »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALX

Alexander's

$379.05

-3.045 (-0.80%)

14:24
01/17/18
01/17
14:24
01/17/18
14:24
Hot Stocks
Alexander's boosts quarterly dividend to $4.50 per share »

Alexander's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$147.07

0.21 (0.14%)

14:22
01/17/18
01/17
14:22
01/17/18
14:22
Hot Stocks
USPTO board says Janssen Oncology patent claims unpatentable »

In a final written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

LOCO

El Pollo Loco

$10.10

-0.2 (-1.94%)

14:20
01/17/18
01/17
14:20
01/17/18
14:20
Options
Bullish option flow in El Pollo Loco »

Bullish option flow in El…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
01/17/18
01/17
14:20
01/17/18
14:20
General news
Fed's Beige Book said the economy continued to expand »

Fed's Beige Book…

$NSD

NASDAQ Market Internals

14:17
01/17/18
01/17
14:17
01/17/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/17/18
01/17
14:16
01/17/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRSP

Crispr Therapeutics

$27.18

-1.34 (-4.70%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Recommendations
Crispr Therapeutics analyst commentary  »

Piper says European…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$54.72

0.12 (0.22%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Technical Analysis
Technical Earnings Preview: Morgan Stanley near 52-week high before news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

INTC

Intel

$43.14

-0.1 (-0.23%)

14:10
01/17/18
01/17
14:10
01/17/18
14:10
Options
Large block of puts in Intel as shares advance »

Large block of puts in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

WRB

W. R. Berkley

$70.12

0.7 (1.01%)

14:09
01/17/18
01/17
14:09
01/17/18
14:09
Hot Stocks
W. R. Berkley combines professional liability units »

W. R. Berkley announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ONTX

Onconova

$1.74

-0.0901 (-4.92%)

14:05
01/17/18
01/17
14:05
01/17/18
14:05
Downgrade
Onconova rating change  »

Onconova downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CY

Cypress Semiconductor

$16.90

-0.17 (-1.00%)

14:05
01/17/18
01/17
14:05
01/17/18
14:05
Options
Cypress Semiconductor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
01/17/18
01/17
14:05
01/17/18
14:05
General news
Apple tax repatriation windfall may total $38 B »

Apple tax repatriation…

14:04
01/17/18
01/17
14:04
01/17/18
14:04
General news
Beige Book says employment, wages grew at modest pace »

The latest Beige Book…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.